Studies Highlight Nuvilex Cell-In-A-Box® Technology Enhances Chemotherapy Effectiveness

Nuvilex, Inc. (OTCQB: NVLX), an emerging biotechnology provider of cell and gene therapy solutions, today discussed the use of the proprietary Cell-in-a-Box® technology, being acquired from SG Austria, as an adjunct to chemotherapy across a spectrum of cancer treatments.

The Cell-in-a-Box® technology involves the encapsulation of cytochrome P450 expressing cells which are placed beside the target tumor. When the patient is injected with the nontoxic drug ifosfamide, the encapsulated cells transform this prodrug into its active, chemotherapeutic drug. The greatest benefit of this treatment protocol is that the treatment is localized to the tumor, enhancing the chemotherapy’s effectiveness.

Most chemotherapy drugs affect both normal and cancerous tissue, which is why they also are toxic to naturally fast-growing cells in the body such as hair follicles and intestinal cells. Ifosfamide was one of many drugs originally used for pancreatic cancer that showed an effect against the tumor, but produced severe side effects. By using encapsulated cytochrome P450 expressing cells to convert the ifosfamide at the tumor site, the encapsulated cell treatment was able to localize the drug's effects within the tumor cells. The amount of drug needed was decreased to only one third of the original dose and the side effects were dramatically decreased.

Dr. Robert Ryan, Chief Executive Officer of Nuvilex, commented, “Our cell encapsulation technology can help practitioners target the tumors while preserving the health of surrounding tissues and avoiding the often fatal side effects that accompany aggressive chemotherapy. We anticipate that by localizing treatment within the target tumors, we will finally have an effective treatment protocol for cancers that also preserves the quality of life.”

About Nuvilex

Nuvilex, Inc. (OTCQB: NVLX) is an emerging international biotechnology provider of live clinically useful, therapeutically valuable, encapsulated cells as well as services for encapsulating live cells for the research and medical communities. Through substantial effort, the aspects of our corporate activities alone and in concert with SG Austria continue to move toward agreement completion and ultimately a strong future. Our company’s ultimate clinical offerings will include cancer, diabetes and other treatments using the company’s industry-leading cell and gene therapy expertise and cutting edge, live-cell encapsulation technology.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 involving risks and uncertainties. Results, events and performances could vary from those contemplated. These statements involve risks and uncertainties which may cause actual results, expressed or implied, to differ from predicted outcomes. Risks and uncertainties include product demand, market competition, and Nuvilex’s ability to meet current or future plans. Investors should study and understand all risks before making an investment decision. Readers are recommended not to place undue reliance on forward-looking statements or information. Nuvilex is not obliged to publicly release revisions to any forward-looking statement, to reflect events or circumstances afterward, or to disclose unanticipated occurrences, except as required under applicable laws.

Copyright Business Wire 2010